Low Weight Loss Response to Incretin Analogs: A Systematic Review.

In 30 seconds

This systematic review examined factors associated with low or absent weight loss among people treated with GLP-1 and GIP analogs for type 2 diabetes or obesity. The abstract identifies higher baseline body weight, BMI, HbA1c, and insulin resistance as predictors of poorer response; it also describes possible contributions from GLP1R variants, adherence, lifestyle, gut microbiome composition, sex, and age. Greater treatment duration was associated with more weight loss, with each additional month linked to greater loss. The abstract provides no pooled effect estimate or sample size.

Key findings

• Higher baseline body weight, BMI, HbA1c, and insulin resistance were associated with lower weight loss response.
• Each additional month of treatment was linked to greater weight loss, and adherence was strongly associated with treatment success.
• GLP1R variants, lifestyle, gut microbiome composition, male sex, and older age were identified as possible response-related factors.

Why it matters

Response to incretin analogs varies, and the factors summarized here may help explain why some patients lose less weight than expected. Considering metabolic status, adherence, and lifestyle alongside possible genetic and demographic influences may support more realistic expectations and inform research toward individualized obesity care. The review also highlights that these predictors require further validation.

What to keep in mind

The abstract reports no pooled quantitative estimate and notes that findings need validation in diverse populations and practical decision tools developed.